Fig. 5.

Priming of tumor-specific class I MHC-restricted human CD8⁺ CTLs by MA and/or LAM from the Aoyama B isolate-activated MDDCs. a Apoptosis of T24 cells treated with MMC was evaluated by flow cytometry using Annexin V and 7-Amino-Actinomycin D. b Percentage of CD1a⁺ PKH67⁺ cells and CD1a⁺ CD141⁺ PKH67⁺ cells in MDDCs co-cultured with T24 cells with/without MMC. Data are shown as the mean ± SD of n = 5 samples per measurement. c Specific lysis of T24 cells and K562 cells by CTLs stimulated by MHC-matched MDDCs co-cultured with MA and/or LAM. d Specific lysis of T24 cells by effector T cells treated with anti-HLA-ABC antibody or depleted of T24-specific CD8⁺ T cells. Graph shows the percent of specific lysis at effector-to-target cell ratio (20/1). Data are shown as the mean ± SD of n = 3 samples per measurement. e Specific lysis of tumor antigen-presenting DCs co-cultured with MA and/or LAM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA followed by Bonferroni post-tests